Comparing Short-Term Outcome after Implantation of the HeartWare® HVAD® and the Abbott® HeartMate 3®

Abstract

Performance of both currently used centrifugal left ventricular assist device systems is comparable in terms of short-term patient survival and freedom from cerebrovascular events. In our single-centre experience, HM3 patients less frequently develop driveline infections and no pump thrombosis, which requires further evaluation.